DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.

NCT Number	NCT06384573
Lead Sponsor	Washington University School of Medicine Collaborators: Alzheimer's Association, Eisai Inc.
Conditions	Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
Enrollment	40 participants
Start Date	2024-06-10
Primary Completion	2030-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-05